Moody Lynn & Lieberson LLC Buys 5,413 Shares of Johnson & Johnson $JNJ

Moody Lynn & Lieberson LLC increased its position in shares of Johnson & Johnson (NYSE:JNJ) by 4.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 122,334 shares of the company’s stock after acquiring an additional 5,413 shares during the quarter. Johnson & Johnson comprises approximately 1.3% of Moody Lynn & Lieberson LLC’s investment portfolio, making the stock its 21st biggest holding. Moody Lynn & Lieberson LLC’s holdings in Johnson & Johnson were worth $25,317,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in JNJ. Fifth Third Wealth Advisors LLC increased its position in shares of Johnson & Johnson by 5.2% in the 4th quarter. Fifth Third Wealth Advisors LLC now owns 39,618 shares of the company’s stock valued at $8,199,000 after buying an additional 1,949 shares in the last quarter. Archford Capital Strategies LLC increased its stake in Johnson & Johnson by 85.7% during the 4th quarter. Archford Capital Strategies LLC now owns 25,023 shares of the company’s stock worth $5,178,000 after purchasing an additional 11,548 shares in the last quarter. Shrier Wealth Management LLC bought a new position in Johnson & Johnson in the fourth quarter valued at approximately $2,579,000. Parkwoods Wealth Partners LLC increased its position in shares of Johnson & Johnson by 16.0% during the fourth quarter. Parkwoods Wealth Partners LLC now owns 1,941 shares of the company’s stock worth $402,000 after acquiring an additional 268 shares in the last quarter. Finally, Strategic Point Investment Advisors LLC acquired a new position in Johnson & Johnson in the 4th quarter worth $223,000. 69.55% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on JNJ shares. HSBC upped their price objective on Johnson & Johnson from $265.00 to $280.00 and gave the stock a “buy” rating in a research report on Tuesday, March 17th. Weiss Ratings reissued a “buy (b)” rating on shares of Johnson & Johnson in a research report on Wednesday, January 28th. Wells Fargo & Company boosted their price target on shares of Johnson & Johnson from $230.00 to $240.00 and gave the stock an “overweight” rating in a research report on Thursday, January 22nd. Stifel Nicolaus lifted their target price on Johnson & Johnson from $205.00 to $220.00 and gave the company a “hold” rating in a research report on Thursday, January 22nd. Finally, Argus boosted their price target on Johnson & Johnson from $210.00 to $240.00 in a research report on Friday, January 23rd. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average target price of $236.91.

Johnson & Johnson Trading Down 0.5%

Shares of Johnson & Johnson stock opened at $242.93 on Friday. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.03 and a quick ratio of 0.77. The business has a fifty day simple moving average of $239.41 and a two-hundred day simple moving average of $212.30. Johnson & Johnson has a 1 year low of $141.50 and a 1 year high of $251.71. The company has a market capitalization of $585.11 billion, a price-to-earnings ratio of 21.98, a P/E/G ratio of 2.42 and a beta of 0.34.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Saturday, January 31st. The company reported $2.46 earnings per share (EPS) for the quarter. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.04%. The company had revenue of $24.28 billion during the quarter. Research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Strong clinical and product momentum — RCT data presented at ACC and published in JACC and JNJ’s recent pace of approvals/med‑tech launches bolster revenue visibility and the company’s long‑term growth story. Why Johnson & Johnson (JNJ) Is One of the Best Pharma Stocks to Invest in Now
• Positive Sentiment: R&D partnership deal — a reported $500M agreement with Royalty Pharma to advance an experimental autoimmune antibody provides non‑dilutive funding and validates JNJ’s pipeline strategy. Royalty Pharma, Johnson & Johnson Strike $500M Autoimmune Drug Deal
• Positive Sentiment: Defensive, dividend appeal — coverage pieces highlight JNJ as a reliable dividend aristocrat and a low‑volatility healthcare hold during market stress, supporting investor demand in uncertain markets. This Healthcare Stock Barely Flinches During Market Sell-Offs
• Neutral Sentiment: Analyst interest and trending status — outlets note JNJ is trending on investor platforms and some analysts expect another earnings beat given its history; this can amplify short‑term flows but isn’t a new fundamental change. Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
• Neutral Sentiment: Major-holder activity — reports show Bridgewater (Ray Dalio) trimmed its position; large-manager moves can influence flows but don’t necessarily reflect company fundamentals. Johnson & Johnson (JNJ): Billionaire Ray Dalio Trims Position
• Negative Sentiment: MedTech China headwinds — previews ahead of Q1 highlight strong cardiovascular and new‑product adoption but warn of slowing demand in China, which is a near‑term earnings risk for the MedTech segment and likely a key reason shares are under pressure. JNJ Q1 MedTech Preview: Key Drivers and China Headwinds to Watch
• Negative Sentiment: Valuation/rotation concerns — after a large one‑year rally, some commentary asks whether returns are largely priced in; combined with periodic profit‑taking, this contributes to downward pressure. Is It Too Late To Consider Johnson & Johnson (JNJ) After Its 61% One-Year Surge?

Insider Buying and Selling

In related news, EVP Vanessa Broadhurst sold 6,197 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the completion of the sale, the executive vice president directly owned 23,003 shares of the company’s stock, valued at approximately $5,598,700.17. This trade represents a 21.22% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Timothy Schmid sold 22,623 shares of Johnson & Johnson stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $244.33, for a total value of $5,527,477.59. Following the sale, the executive vice president directly owned 26,769 shares of the company’s stock, valued at $6,540,469.77. This represents a 45.80% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 30,142 shares of company stock worth $7,360,528. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.